Reasons for Tyndall Capital Partners L P’s Share Sale of Onconova Therapeutics, Inc. (NASDAQ:ONTX)’s Stock

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Logo

Tyndall Capital Partners L P Insider Buy

The Onconova Therapeutics Inc’s insider Tyndall Capital Partners L P sold – 1,247 shares of Onconova Therapeutics Inc, calculated based on the stock price per share of $2.8 per every share. The unloaded insider shares today has a value of exactly $3,432 U.S Dollars. Right now, Tyndall Capital Partners L P possess a total of 795,445 shares or 13.26 % of the Company’s total market capitalization. A report documented published 13/09/2019 with the Security and Exchange Commission, made public here, shows full details for the transaction.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Coverage

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Onconova Therapeutics has $25 highest and $16 lowest target. $20.50’s average target is 720.00% above currents $2.5 stock price. Onconova Therapeutics had 6 analyst reports since March 17, 2019 according to SRatingsIntel. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) on Tuesday, March 26 with “Buy” rating. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) earned “Buy” rating by Maxim Group on Monday, March 25.

The stock decreased 4.94% or $0.13 during the last trading session, reaching $2.5. About 64,761 shares traded or 119.90% up from the average. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 61.81% since September 13, 2018 and is downtrending. It has underperformed by 61.81% the S&P500.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $15.00 million. The company??s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Analysts await Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report earnings on November, 12. They expect $-0.76 earnings per share, up 19.15 % or $0.18 from last year’s $-0.94 per share. After $-0.60 actual earnings per share reported by Onconova Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 26.67 % negative EPS growth.

More notable recent Onconova Therapeutics, Inc. (NASDAQ:ONTX) news were published by: Finance.Yahoo.com which released: “Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT – Yahoo Finance” on August 23, 2019, also Globenewswire.com with their article: “Onconova Therapeutics Announces Presentations at Three Upcoming Conferences – GlobeNewswire” published on May 28, 2019, Streetinsider.com published: “Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results – StreetInsider.com” on August 14, 2019. More interesting news about Onconova Therapeutics, Inc. (NASDAQ:ONTX) were released by: Globenewswire.com and their article: “Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results – GlobeNewswire” published on May 14, 2019 as well as Globenewswire.com‘s news article titled: “Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results – GlobeNewswire” with publication date: March 26, 2019.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.